Your session is about to expire
← Back to Search
Pemigatinib for Advanced Cancer
Study Summary
This trial looks at the safety and tolerability of pemigatinib in patients with advanced malignancies who have participated in a previous study.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 147 Patients • NCT02924376Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this clinical research include elderly individuals?
"This trial is recruiting individuals aged 18 and up to 90 years old."
Is my profile compatible with the requirements of this experiment?
"This clinical trial has capacity for 10 candidates with advanced malignancies between 18 and 90 years old. Eligibility is contingent on the patient's willingness to cooperate, avoid pregnancy or fathering children, and having no evidence of progressive disease following treatment with pemigatinib as monotherapy or combination therapy."
How widespread is this clinical trial across various centers?
"This medical trial is taking place at Virginia Cancer Specialists, PC located in Fairfax, VA and MD Anderson Cancer Center situated in Charlotte, NC as well as Oncology Specialists of Charlotte based out of Santa Monica, CA with an additional 6 sites."
Is enrollment still open for this research endeavor?
"Unfortunately, this medical trial is not currently accepting new candidates. Posted on July 12th 2021 and last updated June 27th 2022, the study remains on hold. Alternately, there are 2376 clinical trials for advanced malignancies enrolling patients and 997 studies involving Pemigatinib actively recruiting participants."
For what maladies is Pemigatinib typically prescribed?
"Pemigatinib is a viable therapeutic option for patients suffering from malignant neoplasms, invasive melanoma, and microsatellite instability high."
How have the safety profiles of Pemigatinib been appraised?
"Our team at Power has assigned a score of two to Pemigatinib, as clinical data exists in support of its safety but efficacy remains unproven."
Are there any precedents to using Pemigatinib for research purposes?
"Pemigatinib was initially studied at City of Hope in 2010. Since then, the drug has been tested in 260 completed clinical trials and is now under investigation for 997 separate studies across a variety of locations including Fairfax, Virginia."
How many individuals are currently participating in this clinical research?
"As of the latest update on June 27th 2022, this clinical trial is not accepting new participants. If you are seeking alternative studies, there are 2376 trials recruiting participants with advanced cancer and 997 for Pemigatinib specifically in progress."
Share this study with friends
Copy Link
Messenger